Potential for Systemic Therapy in the Adjuvant Setting of HCC
Masatoshi Kudo, MD, PhD, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma. While current trials are investigating this therapy in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.
Masatoshi Kudo, MD, PhD, professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University in Osaka, Japan, discusses the potential for systemic therapy in the adjuvant setting of hepatocellular carcinoma (HCC). While systemic therapy is currently only developed in advanced stage HCC, Kudo believes it could benefit patients following a surgery resecting an aberration.
Kudo says that this therapy has produced a very high response rate, showing potential for its use in the adjuvant setting. Because HCC is known for recurrence, patients could benefit from this therapy being used early on.
